Tumor Treating Fields (TTFields), also known as electric fields therapy, uses low-intensity electric fields to disrupt cancer cell division, thereby inhibiting tumor growth and enhancing patient outcomes. The TTFields modality relies on alternating electric fields of intermediate frequencies (100-300 kHz) to exert anti-mitotic effects and selectively impact dividing cancer cells during specific phases of mitosis. By delivering localized treatment through transducer arrays applied to the skin, TTFields act as a standalone or adjunctive anti-cancer therapy across tumor types including glioblastoma, non-small cell lung cancer, and pancreatic cancer.
The Tumor Treating Fields market consists of medical devices and accessories for delivering TTFields therapy to cancer patients. Its non-invasive nature and ability to improve survival rates make TTFields an appealing modality for targeted localized treatment of solid tumors. TTFields are well-tolerated with mild skin irritation being the most common side effect. The technology provides real-time dosimetry to ensure effective and safe electric field distribution throughout tumor tissues. With additional regulatory clearances and clinical evidence, the market for Tumor Treating Fields therapy is poised to grow significantly.
The Global Tumor Treating Fields Market is estimated to be valued at US$ 384.54 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Tumor Treating Fields Market Size are Tier 1 Companies (DS Smith PLC, Crown Holdings Inc., Ardagh Group, WestRock Co., Owens-Illinois Inc., International Paper Company Inc., Amcor PLC, Delta Global, GPA Global), and Tier 2 Companies (HH Deluxe Packaging, Prestige Packaging Industries, Pendragon Presentation Packaging, Stolzle Glass Group, Keenpac, Elegant Packaging, BC Boncor, Luxpac Ltd, McLaren Packaging Ltd, and B Smith Packaging Ltd).
The growing demand for targeted and non-invasive treatment options along with rising cancer incidence worldwide is fueling the adoption of Tumor Treating Fields therapy. TTFields devices enable outpatient cancer treatment and prolonged progression-free survival, increasing patient compliance and quality of life.
Major players are engaged in expanding global access to Tumor Treating Fields therapy through regulatory clearances and geographic footprint. Novocure, the pioneer of TTFields therapy, has established commercial presence in over 30 countries and seeks approvals for additional tumor indications. Regional players also pursue international collaborations to meet the growing needs of cancer patients globally.
Market Key Trends
The key trend enabling growth of the Tumor Treating Fields market is increased clinical evidence demonstrating efficacy and survival benefits across different cancers. Pivotal trials have established TTFields as the new standard of care for recurrent glioblastoma and led to approvals for first-line glioblastoma and mesothelioma. Ongoing studies evaluate its role in lung, breast, ovarian and other solid tumors. This expanding evidence base convincing more medical practitioners to adopt Tumor Treating Fields is increasing its Market penetration. Other significant trends include technological advancements to TTFields generators for optimized field delivery and expanded reimbursement in favorable territories boosting commercial availability of this transformative cancer treatment modality.
Porter’s Analysis
Threat of new entrants: Low costs of entry and established brands have a competitive advantage.
Bargaining power of buyers: Large healthcare providers have more negotiating power over pricing and product design.
Bargaining power of suppliers: Suppliers of raw materials and key components have some control over pricing.
Threat of new substitutes: Alternative cancer treatment methods can threaten market share over time.
Competitive rivalry: Market dominated by few major players with others competing on product innovations.
Geographical Regions
North America holds the largest share of the tumor treating fields market, estimated at around 35% in 2024. High healthcare spending capabilities and presence of major players drive the region’s market value.
The Asia Pacific regional market is projected to expand at the fastest pace during the forecast period. Increasing incidence of cancer cases and growing medical tourism are factors influencing the region’s tumor treating fields market growth prospects. Rapid economic development in countries like China and India is supporting investments towards advanced cancer therapies.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it